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Background. Bremsstrahlung (BS) imaging during radioembolization (RE) confirms the deposition of radiotracer in hep-
atic/extrahepatic tumors.The aim of this study is to demonstrate 32P images and to optimize the imaging parameters.Materials and
Methods.Thirty-nine patients with variable types of hepatic tumors, treatedwith the intra-arterial injection of 32P,were included. All
patients underwent BS SPECT imaging 24–72 h after tracer administration, using low energy high resolution (LEHR) (18 patients) or
medium energy general purpose (MEGP) (21 patients) collimators. A grading scale from 1 to 4 was used to express the compatibility
of the 32P images with those obtained from CT/MRI. Results. Although the image quality obtained with the MEGP collimator was
visually and quantitatively better thanwith the LEHR (76%concordance score versus 71%, resp.), therewas no statistically significant
difference between them. Conclusion. The MEGP collimator is the first choice for BS SPECT imaging. However, if the collimator
change is time consuming (as in a busy center) or an MEGP collimator is not available, the LEHR collimator could be practical
with acceptable images, especially in a SPECT study. In addition, BS imaging is a useful method to confirm the proper distribution
of radiotherapeutic agents and has good correlation with anatomical findings.
1. Introduction
Radioembolization (RE) is a promising therapeutic modality
for patients with unresectable hepatic tumors. In this proce-
dure, radioisotopes preferentially localize in the peritumoral
and intratumoral arterial vasculature, while exposure to the
normal hepatic parenchyma remains within tolerable limits.
RE is based on the predominant arterial blood supply of
hepatic tumoral lesions by the hepatic artery, in contrast
to normal liver parenchyma, which is mainly supplied by
the portal vein [1, 2]. Therapeutic agents are properly sized
pharmaceuticals which incorporate the 𝛽 radiating isotopes,
such as 90Y, 188Re, and 166Ho [3–5]. The clinical applications
of these 𝛽+ emitters for the treatment of different kinds
of malignant and nonmalignant diseases are increasing [6].
Posttreatment imaging confirms the distribution of radio-
tracers within the target organ, or an additional unexpected
deposition [7]. These data help the physician to predict the
patient’s response to RE therapy or the probable side effects
[7].
In this study, phosphorus-32 (32P) particles were used
for the RE of hepatic tumors. Phospherous-32, a pure 𝛽+
emitter available as a therapeutic radiopharmaceutical since
the 1960s, has many suitable features for radioembolization
therapy, such as a long half-life (14.3 days) and a maximum
energy of 1.7MeV. However, secondary photon emissions,
called Bremsstrahlung (BS), produce a broad spectrum of
limited energies and, therefore, compromise the selection of
Hindawi Publishing Corporation
Radiology Research and Practice
Volume 2014, Article ID 407158, 7 pages
http://dx.doi.org/10.1155/2014/407158
2 Radiology Research and Practice
energy windows and collimation, as well as the reconstruc-
tion of the SPECT images [8, 9].
Most studies which assess the parameters for the BS
imaging of pure 𝛽 emitters (e.g., 32P or 90Y) have used
phantoms [9–16], and there is a gap in the comprehensive
research to evaluate these factors in clinical practice. This
study was designed to optimize the imaging parameters,
including the energy window and collimator type for BS
imaging. In addition, we evaluated the correlation of this
technique with the anatomical findings in patients with
hepatic tumors being treated with RE.
2. Materials and Methods
A total of 39 patients with unresectable hepatic or metastatic
tumors of any origin, which were candidates for RE [17]
with 32P particles, were included in this study. The chromic
phosphate 32P radiopharmaceutical, with a mean size of
50–150𝜇m and a mean injected activity of 260MBq (75–
450MBq), was produced locally at the research reactor
(IAEO, Iran). Calculations of the appropriate radiation dose
were undertaken according to the following formula: dose
(Gy) = 7.3 × activity (mCi)/hepatic mass (kg) [18].
This study complies with the declaration of Helsinki
and was approved by the institutional ethics committee of
the Shahid Beheshti University of Medical Sciences, and all
patients provided written informed consent.
2.1. Anatomical Imaging. Cross-sectional imaging with a
CT or MRI was accomplished for all patients in order to
determine the size and location of the lesions as numerical
segments consistent with the physiological division of Couin-
aud [19]. The findings were reported by a radiologist, and the
liver volume was calculated.
2.2. Radioembolization Procedure. The standard
angiographic method for the assessment of the femoral
artery was used [20]. The celiac and superior mesenteric
arteries were catheterized using a Cordis Simon I catheter,
and DSA angiography was prepared using a Siemens’ C-Arm
Angiography Unit. Superselective catheterization was done
using Cook’s 3Fmicrocatheter and 32P particles were injected
into the artery. Afterwards, a postembolization angiogram
was obtained [21].
2.3. Bremsstrahlung Imaging. Imaging was conducted 24–72
hours after the RE of the hepatic tumors.The imaging system
consisted of a Siemens single head e.cam gamma camera
equipped with a low energy high resolution (LEHR) or a
mediumenergy general purpose (MEGP) collimator. In order
to select the window setting, the BS energy spectra with the
LEHR and MEGP collimators were obtained using a 37MBq
32P point source, in a glass vial placed at a distance of 10 cm
from the collimator in the center of the field of view (FOV).
An energy window setting of 100 keV ± 25% was chosen.
All patients were randomly divided into two groups, A
andB. In groupA, planar and SPECT imagingwere donewith
the LEHR collimator, whereas an MEGP collimator was used
in group B. Planar imagingwas performed in the anterior and
posterior projections of the upper abdomen for 10 minutes,
using a 64 × 64 matrix. In the SPECT study, the data were
acquired in a 64 × 64 matrix for 64 projections over 360∘,
for a period of 30 seconds per projection. Raw data were
reconstructed from either filtered-back projections or iter-
ative (ordered subsets expectation maximization (OSEM))
methods [22]. The OSEM method with four iterations and
two subsets was selected as the method of choice for the
reconstruction due to fewer image distortions. The images
were reconstructed in transaxial, sagittal, and coronal slices.
2.4. Image Interpretation. The images obtained from the
SPECT and CT/MRI were evaluated visually by two nuclear
medicine specialists and one radiologist in a blinded and
independent fashion. A linear black and white scale with
a lower and upper threshold of 0% and 100%, respectively,
was used for all planar and SPECT images. The distribution
of 32P in the liver was assessed and reported as focal or
multifocal lesions in the involved segments. Based on the
compatibility of the 32P images with anatomical findings
(CT/MRI), a grading system proposed by Boan et al. [23] was
applied per patient as grade 4 for poor correlation, grade 3
for intermediate correlation, grade 2 for good correlation, and
grade 1 for a perfect match. In cases of disagreement between
the physicians, a consensus was reached. The extrahepatic
activity was also reported.
2.5. Statistical Analysis. Continuous variables were expressed
as the mean ± SD, and categorical variables were expressed
as absolute values and percentages. A 2-tailed 𝑡-test was used
to compare the mean values between the groups. The Mann-
Whitney𝑈 test was used to compare the statistical differences
between the LEHR and the MEGP collimators as a grading
system. A𝑃 value of less than 0.05 was considered statistically
significant. All statistical analyses were performed using an
IBM computer and the SPSS Inc. PASW software, version
18.0.
3. Results
Thirty-nine patients with a variety of hepatic tumoral lesions
were treated with RE and evaluated (Table 1). The choice
of energy window shows the 32P BS energy spectra taken
with a gamma camera equipped with the LEHR and MEGP
collimators (Figure 1). In contrast to the standard gamma
emitters, the energy spectrum of the BS is very complex, with
no pronounced photopeak. The lowest detectable energy in
the spectra is about 25 keV, with a peak of around 75 and
150 keV. Considering these spectra, the energy window was
set at 100 keV ± 25% for all measurements. The number of
measured photons was significantly reduced with the MEGP
resulting in a reduced sensitivity.
Regarding the effect of the collimator type, 18 patients
in group A were imaged with the LEHR collimator and 21
patients in group B, with the MEGP collimator. In addition,
the planar and SPECT images from the LEHR and MEGP
collimators were obtained (Figure 2). A comparison of the
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Figure 1: P-32 Bremsstrahlung energy spectra with (a) LEHR collimator and (b)MEGP collimator, obtained using a 37MBq 32P point source,
in a glass vial, at a distance of 10 cm from the collimator.
Table 1: Characteristics of patients treated with RE.
Age 54 yr. (27–78)
Sex 𝑛 = 39
Male 20
Female 19
Primary cancer
Colon 25
Breast 5
HCC 3
Carcinoid 3
Pancreas 1
Lung 2
CT/MRI and BS SPECT images as the correlative grading
score between the MEGP and LEAP collimators is summa-
rized in Table 2. There is a good or perfect correlation with
the anatomical findings (scores 1 and 2) in 13 (71%) BS images
from group A (LEHR collimator), and in 16 (76%) from
group B (MEGP collimator). However, this difference is not
statistically significant (𝑃 value = 0.9). Taken as a whole, in 29
patients (74%) the BS images have a satisfactory concordance
(Figure 3). A perfect concordance of the SPECT and CT
images of a necrotic tumor is demonstrated in Figure 4.
Some unusual findings were also recorded. The extra-
hepatic accumulation of the radiotracer was observed in the
spleen of two patients, duodenum of one patient, and the
pancreas of one patient (see Figure 5).
4. Discussion
The application of the 𝛽+ emitting radionuclides for the
treatment of malignant and nonmalignant conditions is
increasing [6]. In these cases, imaging can be performed
by measuring the BS photons emitted from the 𝛽 particles
as they lose their energy in the body [24]. BS radiation is
not ideal for diagnostic purposes, because of the continuous
energy range, interseptal penetration of high energy photons,
and the creation of photons far from the radiation emission
site [9, 10]. Despite these problems, BS imaging is important
in confirming the satisfactory delivery, pharmacokinetics,
and potential abnormal deposition of the radiotracer [16, 25–
29]. Furthermore, it has been demonstrated that BS imaging
Table 2: Correlation grading for compatibility of 32P images
obtained by the LEHR collimator and the MEGP collimator, with
anatomical findings.
LEAP MEGP Total
Score 1 1 2 3
Score 2 4 3 7
Score 3 6 8 14
Score 4 7 8 15
Total 18 21 39
is useful for the direct quantification and dosimetry of 𝛽-
emitter isotopes in clinical practice [4, 30–32]. We evaluated
optimized parameters for 32P BS imaging after the RE of the
hepatic tumors, and to our knowledge, this is the first clinical
study to assess these factors to improve image quality.
As a result of the complexity of the spectrum and the
absence of a pronounced photopeak, the task of selecting a
suitable energy window was particularly difficult. Further-
more, the optimal energywindow for a particular beta emitter
is still a matter of debate within the research community [24].
Considering the 32P BS spectrum (Figure 1) and the results of
other studies [26, 30, 33, 34], the energy window of 100 keV
+ 25% was selected. As shown in Figure 1, the lower energy
(about 75 keV) of the 32PBS energy spectra is compatible with
the X-ray characteristics due to the interaction of the high
energy BS photons which lead the septa of the collimator.The
rise in the spectrum of about 150 keV reflects the penetration
of the septa of the collimators by higher energy. The same
phenomenon has been previously reported in 32P, 90Y, and
89Sr BSmeasurements with a gamma camera [9–11, 13, 15, 27].
Although the maximum energies of 32P and 90Y are different
(1.7MeV vs. 2.27MeV), their BS spectra appear to be similar.
Ito et al. [11] compared different energy windows for BS 90Y
imaging and concluded that images obtained with an energy
window of 120 keV + 15% provided the highest resolution and
lowest uncertainty. Shen et al. [9] showed that the best and
most practical selection is an energy window of 55–285 keV.
Therefore, the selection of the energy window varies with
each study. Some researchers select narrow energy windows
[16, 26, 34, 35], while others prefer wider ranges [7, 10, 29]
depending on the purpose of the imaging; if the goal is
4 Radiology Research and Practice
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Figure 2: A patient with metastatic colon cancer treated with 333MBq 32P particles. (a) Bremsstrahlung 32P images in planar study with
LEHR and MEGP collimators. (b) Bremsstrahlung 32P images in SPECT study with LEHR and MEGP collimators.
Figure 3: A patient with metastatic colon cancer treated with 296MBq 32P particles. It shows a perfect concordance of Bremsstrahlung and
CT images (grade 1).
accurate localization of distributed activity, a narrower range
is ideal.
In this study, we examined the collimator type for 32P BS
imaging. Thirty-nine patients were divided into two groups,
with anLEHRcollimator in groupAand anMEGPcollimator
in group B. The other imaging parameters were similar in
both groups. In comparison to the anatomical images, the
concordance scores of the SPECT images in groups A and B
were statistically insignificant. The MEGP collimator created
higher quality images because of lower septal penetration
background activity, compared to the LEHR. Meanwhile, the
LEHR collimator did create acceptable images, particularly
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Figure 4: (a) Enlarged necrotic tissue secondary to previous chemoembolization (nonradioactive lipiodol) and (b) correlated CT slice.
Anterior 84K 64 × 64 Posterior 69K 64 × 64
Figure 5: Unusual findings of splenic activity visualized after RE with 32P particles.
in the SPECT study (Figures 2 and 3). In a quantitative
study on the planar images using the phantom, Shen et al.
[9] showed that the sensitivity of the LEAP collimator was
three times better than that of the MEGP collimator, whereas
the system resolution of the MEGP collimator was three
times better than that of the LEAP collimator. Similar results
were obtained by Cipriani et al. [15] and Shukla et al. [13].
Therefore, most researchers working on BS imaging have
usedME [7, 10, 11, 15, 25–30, 33–37] orHE collimators [16, 32].
In this study, we selected the narrow energy window
and used the LEHR collimator (instead of the LEAP),
which relatively improved the system resolution. In addition,
compared to planar images, the SPECT method improves
lesion contrast and anatomical clarity by the removal of
superimposed radioactivity [38]. These factors influenced
lesion detectability; thus, it could be concluded that the
MEGP collimator is the best choice for BS SPECT imaging.
However, if the collimator change is time-consuming (as in
a busy center) or the MEGP collimator is not available, the
LEHR collimator could be practical as it creates acceptable
images, especially in SPECT studies.
Despite the inherently poor resolution of BS imaging, as
our previous study showed, there is a relatively good correla-
tion between BS imaging and the CT/MRI or other nuclear
medicine studies [39]. Mansberg et al. [28] showed that BS
images have anatomical correlations with sites containing
maximum tumor density. Similarly, Tehranipour et al. [37]
described concordant findings from the 18F-FDG PET and
90Y-Bremsstrahlung scans after the RE of a hepatic tumor in
one case report. The correspondence of the 99mTc-MDP and
89Sr BS images was also reported [15, 35, 40].
Our study showed a relatively good correlation between
the SPECT and CT/MRI images (Table 2). The results of this
study reveal that BS SPECT images have adequate resolution
for posttreatment evaluations, and that 74 percent of patients
have good correlation or a perfect match with the CT/MRI
images, confirming the technically appropriate localization of
the radiopharmaceuticals. As such, a potential good response
to therapy can be predicted. Conversely, a poor correlation
could be due to small metastatic lesions undetectable in
BS images because of an inherently low spatial resolution.
Furthermore, the distribution of particles could be affected
during intra-arterial injections by vessel selection, the flow
in a selected vessel, or the size and amount of the injected
particles. Discordant findings can also be related to techni-
cal errors (such as a superselective intra-arterial injection)
during the RE, or poor vascularized hepatic tumors, thereby
leading to the accumulation of radiotracers in normal tissues
[26, 33, 41]. In contrast to concordance cases, the therapeutic
response will not be ideal in discordant cases because of
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inadequate radiation to the target [26]. We will, however,
evaluate the clinical applications of the anticipated grading
system in an ongoing study.
The potential advantage of 32P scintigraphy is its ability
to depict the vascularity of viable tumor cells rather than
the necrotic tissue of a tumor mass (Figure 5). Therefore, BS
imaging of P-32 after the RE of the hepatic tumors can be
reflective of vascularized and viable tumoral tissues [33].
The extrahepatic deposition of radiotracers is an impor-
tant finding, which can assist physicians in subsequent
treatment planning. The extrahepatic activity in the spleen
(Figure 4), lung, and GI tract can have probable unwanted
complications. In addition, because of the lower delivered
radiation dose to the target, failure in the treatment can be
predicted. Ahmadzadehfar et al. demonstrated the impor-
tance of BS imaging to predict RE-induced extrahepatic
side effects [29]. Sebastian et al. [26] have also reported
gastric ulcerations as a result of microspheres entering into
an aberrant gastric artery.
It should be mentioned that the current study had some
limitations. One of the most important drawbacks is its small
sample size. Another limitation is that we did not perform
an angiogram with Tc-MAA to rule out a possible high lung
shunt; however, further evidence needs to be acquired.
5. Conclusion
Despite the shortcomings of BS imaging, good quality images
can be obtained by the optimization of the energy window
and collimator type. BS imaging of 32P, after the RE of
hepatic tumors, can confirm the hepatic and extrahepatic
distribution of radiotracers to predict the patient’s response
to RE therapy.This study shows that an LEHR collimatormay
produce acceptable images, especially for the SPECT.
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